Covid-19 treatment

Gohibic (vilobelimab) has been granted an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the treatment of Covid-19 in hospitalised adults. The monoclonal anti-human complement factor C5a antibody should be initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). Professor Niels C Riedemann, CEO […]

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery.  AstraZeneca has initiated the SUPERNOVA Phase I/III trial of AZD5156 (a combination of AZD3152 and cilgavimab) in pre-exposure prophylaxis of Covid-19, following the company licensing AZD3152 from RQ Bio in May 2022.   The commencement of […]

New research suggests messenger RNA can be effectively used as a ‘universal’ therapy against different coronaviruses.  A scientist at Oregon State University has demonstrated in a mouse model that it’s possible to prompt the production of a protein that can block multiple variants of the SARS-CoV-2 virus from entering cells and causing respiratory disease.  “Rather […]